Axsome Therapeutics, Inc.

NEW YORK, NY · Founded 2012 · Biotech · Public

Small-molecule therapeutics for CNS conditions including AXS-05, AXS-12, and AXS-14

Claim this profile

Follows are private to you and power your alerts

Updated · axsome.com

Sector
Biotech
Headquarters
NEW YORK, NY
Founded
2012
Latest Form D
$2.5M, May 2015
Total capital
$7.2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$7.2M
5 Form D · last May 2015
137 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
9
31 pending · first 2026
Rank in peer group#10 of 1449

Capital timeline

201320142015FEDERAL ↑EQUITY ↓Cumulative $7.2M1st Form D$211K2nd Form D$1.2M3rd Form D$2M5th Form D$2.5M
201320142015FEDERAL ↑EQUITY ↓Cumulative $7.2M3rd Form D$2M5th Form D$2.5M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$2.5M
  • Private capital raisedForm D · SEC · 4th filing$1.3M
  • Private capital raisedForm D · SEC · 3rd filing$2M
  • Private capital raisedForm D · SEC · 2nd filing$1.2M
  • Private capital raisedForm D · SEC · 1st filing$211K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#10 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Herriot TabuteauExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 9 granted of 40
  • PendingPharmaceutical Compositions Comprising MeloxicamUSPTOApplication 19455676
  • PendingPharmaceutical Compositions Comprising MeloxicamUSPTOApplication 19076089
  • PendingCarbamoyl Phenylalaninol Compounds As TAAR1 AgonistsUSPTOApplication 18870855
Show all 40 patent records
  • Pharmaceutical Compositions Comprising MeloxicamSep 17, 2026 · Application 19455676Pending
  • Pharmaceutical Compositions Comprising MeloxicamSep 17, 2026 · Application 19076089Pending
  • Carbamoyl Phenylalaninol Compounds As TAAR1 AgonistsSep 3, 2026 · Application 18870855Pending
  • Pharmaceutical Compositions Comprising MeloxicamSep 3, 2026 · Application 19458316Pending
  • Pharmaceutical Compositions Comprising MeloxicamSep 3, 2026 · Application 19457014Pending
  • Pharmaceutical Compositions Comprising MeloxicamAug 13, 2026 · Application 19646069Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 30, 2026 · Application 19423882Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 30, 2026 · Application 19074873Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 30, 2026 · Application 19306984Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 28, 2026 · US 12,691,123Granted
  • Pharmaceutical Compositions Comprising Uniform Blends Of EsreboxetineJul 23, 2026 · Application 19172485Pending
  • (S)-2-((S)-(2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINEJul 23, 2026 · Application 19532952Pending
  • Dosage Forms Containing Esreboxetine Having Improved PurityJul 23, 2026 · Application 19437961Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 21, 2026 · US 12,685,736Granted
  • Methods And Compositions For Improving Driving PerformanceJul 16, 2026 · Application 19134503Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 9, 2026 · Application 19390397Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 9, 2026 · Application 19399454Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 2, 2026 · Application 19390405Pending
  • Pharmaceutical Compositions Comprising MeloxicamJul 2, 2026 · Application 19390403Pending
  • Dosage Forms Containing Reboxetine Having Improved PurityJun 25, 2026 · Application 19091414Pending
  • Pharmaceutical Compositions Comprising Uniform Blends Of ReboxetineJun 25, 2026 · Application 19079284Pending
  • 2-((2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINEJun 25, 2026 · Application 19088674Pending
  • Pharmaceutical Compositions Comprising MeloxicamJun 18, 2026 · Application 19529640Pending
  • Compositions And Methods For Treating InsomniaMay 21, 2026 · Application 19119531Pending
  • Use Of Reboxetine To Treat NarcolepsyMay 21, 2026 · Application 19317671Pending
  • Use Of Reboxetine To Treat NarcolepsyMay 5, 2026 · US 12,616,702Granted
  • Pharmaceutical Compositions Comprising MeloxicamMay 5, 2026 · US 12,616,752Granted
  • Pharmaceutical Compositions Comprising MeloxicamApr 28, 2026 · US 12,611,413Granted
  • Use Of Reboxetine To Treat NarcolepsyApr 9, 2026 · Application 19417205Pending
  • Solid Forms Of Enantiopure Deuterium-enriched Bupropion And Methods Of Use ThereofMar 26, 2026 · Application 19404599Pending
  • Pharmaceutical Compositions Comprising MeloxicamMar 19, 2026 · Application 19367653Pending
  • Pharmaceutical Compositions Comprising MeloxicamMar 12, 2026 · Application 19196655Pending
  • (S)-2-((S)-(2-ETHOXYPHENOXY)(PHENYL)METHYL)-4-NITROSOMORPHOLINEMar 3, 2026 · US 12,565,478Granted
  • Pharmaceutical Compositions Comprising MeloxicamFeb 17, 2026 · US 12,551,488Granted
  • Pharmaceutical Compositions Comprising MeloxicamFeb 17, 2026 · US 12,551,489Granted
  • Use Of Reboxetine To Treat NarcolepsyFeb 12, 2026 · Application 19359586Pending
  • Methods Of Treating Migraines With A Combination Of A Meloxicam And A RizatriptanFeb 10, 2026 · US 12,544,383Granted
  • Pharmaceutical Compositions Comprising MeloxicamJan 29, 2026 · Application 19085084Pending
  • Use Of Reboxetine To Treat FibromyalgiaJan 15, 2026 · Application 19272981Pending
  • Use Of Esreboxetine To Treat Nervous System Disorders Such As FibromyalgiaJan 15, 2026 · Application 19278727Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .